Avalon/GSK Incubation Project Launches First Company, Focused On Celiac Disease

This article was originally published in The Pink Sheet Daily

22 Nov 2013
News

Executive Summary

New company Sitari will try to develop first drug therapy for celiac disease. Portfolio companies launched by GSK and Avalon also will have their own, dedicated CRO-like organization to handle much of their work.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Europe

United Kingdom

Related Companies

Related Deals

AbbVie pays for option to acquire Alvine equity or its celiac disease compound

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States United Kingdom

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS075082

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS075082

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Avalon/GSK Incubation Project Launches First Company, Focused On Celiac Disease

News

Executive Summary

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert